| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/11/2009 | US20090149397 Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| 06/11/2009 | US20090149389 Kinase Inhibitors And Uses Thereof |
| 06/11/2009 | US20090149382 Modulation of lipid rafts |
| 06/11/2009 | US20090148854 Can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization |
| 06/11/2009 | US20090148834 Methods of use of alpha-methylacyl-CoA racemase in hormone refractory and metastatic prostate cancers |
| 06/11/2009 | US20090148535 Method for treating cancer using interference rna |
| 06/11/2009 | US20090148531 Rate-controlled particles |
| 06/11/2009 | US20090148471 Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen |
| 06/11/2009 | US20090148461 Anti fgf23 antibody and a pharmaceutical composition comprising the same |
| 06/11/2009 | US20090148460 Exosome ligands, their preparation and uses |
| 06/11/2009 | US20090148459 Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents |
| 06/11/2009 | US20090148457 Hepatocyte growth factor receptor antagonists and uses thereof |
| 06/11/2009 | US20090148452 Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| 06/11/2009 | US20090148451 Therapeutic anti-cytomegalovirus compounds |
| 06/11/2009 | US20090148448 Methods and compositions for modulating and detecting wisp activity |
| 06/11/2009 | US20090148445 Methods of sensitizing cancer to therapy-induced cytotoxicity |
| 06/11/2009 | US20090148441 Anti-Cancer Antibodies With Reduced Complement Fixation |
| 06/11/2009 | US20090148439 by use of a polypeptide (CD27L); in particular kidney cancer; monitoring the effectiveness of epithelial-derived cancer therapy |
| 06/11/2009 | US20090148403 Interleukin-9 Antagonist Muteins and Their Pharmacological Methods of Use |
| 06/11/2009 | US20090148400 Composition of tumour-associated peptides and related anti-cancer vaccine |
| 06/11/2009 | US20090148396 Biocompatible biodegradable fumagillin analog conjugates |
| 06/11/2009 | US20090148384 Functionalized, solid polymer nanoparticles comprising epothilones |
| 06/11/2009 | CA2708223A1 Oral compositions of abt-263 for treating cancer |
| 06/11/2009 | CA2708050A1 Method for expanding hematopoietic stem cells using heterocyclic compound |
| 06/11/2009 | CA2707989A1 Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| 06/11/2009 | CA2707718A1 Abcg2 inhibitor |
| 06/11/2009 | CA2707689A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 06/11/2009 | CA2707653A1 Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| 06/11/2009 | CA2707585A1 Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders |
| 06/11/2009 | CA2707554A1 Use of 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| 06/11/2009 | CA2707444A1 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| 06/11/2009 | CA2707443A1 Conjugates of anti-rg-1 antibodies |
| 06/11/2009 | CA2707308A1 Ido inhibitors |
| 06/11/2009 | CA2706933A1 Nanoparticles of therapeutic agents having low water solubility |
| 06/11/2009 | CA2706926A1 Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| 06/11/2009 | CA2706923A1 Intravesical compositions with valrubicin for the treatment of bladder cancer |
| 06/11/2009 | CA2706914A1 Biocompatible biodegradable fumagillin analog conjugates |
| 06/11/2009 | CA2706907A1 Cancer vaccine composition |
| 06/11/2009 | CA2706337A1 Method of inhibition of leukemic stem cells |
| 06/11/2009 | CA2704266A1 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| 06/11/2009 | CA2703790A1 Anti-vegf antibodies |
| 06/11/2009 | CA2701071A1 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| 06/10/2009 | EP2067792A2 Inhibitory antibodies of HER3 activity |
| 06/10/2009 | EP2067791A1 Prophylactic or therapeutic agent for cancer |
| 06/10/2009 | EP2067775A1 Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors |
| 06/10/2009 | EP2067771A1 Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds |
| 06/10/2009 | EP2067488A1 Albumin fusion proteins |
| 06/10/2009 | EP2067486A1 Use of CD23 antagonists for the treatment of neoplastic disorders |
| 06/10/2009 | EP2067472A1 Compositions and methods for the diagnosis and treatment of tumor |
| 06/10/2009 | EP2066696A1 Anti-cancer antibodies against lewisy and lewisb antigens |
| 06/10/2009 | EP2066682A2 Crystalline forms of valrubicin and processes for their preparation |
| 06/10/2009 | EP2066680A1 Triphenylphosphonium thionitrite nitric oxide donors |
| 06/10/2009 | EP2066679A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 06/10/2009 | EP2066676A1 HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| 06/10/2009 | EP2066673A2 Tricyclic compounds and its use as tyrosine kinase modulators |
| 06/10/2009 | EP2066672A1 An improved process for the preparation of temozolomide and analogs |
| 06/10/2009 | EP2066647A1 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors |
| 06/10/2009 | EP2066632A1 Benzophenone derivatives useful for inhibiting formation of microtubule |
| 06/10/2009 | EP2066627A1 Novel minor groove binders |
| 06/10/2009 | EP2066341A1 Method of eliciting or inducing an immune response |
| 06/10/2009 | EP2066328A2 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| 06/10/2009 | EP2066327A2 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
| 06/10/2009 | EP2066324A2 Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
| 06/10/2009 | EP2066320A1 Methods and compositions for treating lymphoma and myeloma |
| 06/10/2009 | EP2066319A1 Benzotriazole kinase modulators |
| 06/10/2009 | EP2066318A2 Oxindole derivatives as anticancer agents |
| 06/10/2009 | EP2066315A1 Treatment of pain using satraplatin |
| 06/10/2009 | EP2066311A2 Second line treatment of metastatic hormone refractory prostate cancer using satraplatin |
| 06/10/2009 | EP1877559A4 Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers |
| 06/10/2009 | EP1711499B1 Fused pyrrolocarbazoles and methods for the preparation thereof |
| 06/10/2009 | EP1684809A4 Chelate based scaffolds in tumor targeting |
| 06/10/2009 | EP1601673B1 Fused heterocycles and uses thereof |
| 06/10/2009 | EP1597251B1 Pyrimidine compounds |
| 06/10/2009 | EP1579870B1 Vaccines comprising polynucleotides |
| 06/10/2009 | EP1532105B1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof |
| 06/10/2009 | EP1319003B1 Xanthine phosphodiesterase v inhibitors |
| 06/10/2009 | EP1141004B1 Proteins from rana pipiens and their use in the treatment of tumors |
| 06/10/2009 | EP0854870B1 Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| 06/10/2009 | DE202009001822U1 Prophylaxemittel gegen Krebskrankheiten und erhöhte Hautspannungen Prophylaxis for cancer diseases and increased skin tension |
| 06/10/2009 | DE102007058747A1 Nichtsteroidale Progesteronrezeptor-Modulatoren Non-steroidal progesterone receptor modulators |
| 06/10/2009 | CN101450934A Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 06/10/2009 | CN100497639C Means and methods for the production of adenovirus vectors |
| 06/10/2009 | CN100497628C Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 06/10/2009 | CN100497605C Anti cancer targeted regulatory gene-virus and construction method thereof |
| 06/10/2009 | CN100497601C Human myeloma cell line |
| 06/10/2009 | CN100497392C Antagonistic anti-hTNFSF13b Human antibodies |
| 06/10/2009 | CN100497389C Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 06/10/2009 | CN100497388C Antibody selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and use thereof |
| 06/10/2009 | CN100497387C Chimeric proteins for cell targeting and apoptosis induction and methods of using same |
| 06/10/2009 | CN100497386C Antibodies of non-functional P2X7 receptor and its uses |
| 06/10/2009 | CN100497385C Antibodies of non-functional P 2 Chi 7 receptor and its uses of diagnosis and treatment of cancers and other syndrome |
| 06/10/2009 | CN100497339C Pyrimido compounds |
| 06/10/2009 | CN100497323C New heterocyclic oxime compounds, preparing process and medical composition thereof |
| 06/10/2009 | CN100497314C Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
| 06/10/2009 | CN100497313C New isoquinoline compounds, their preparation method and medicine composition containing them |
| 06/10/2009 | CN100497302C Diarylurea derivatives and their use as chloride channel blockers |
| 06/10/2009 | CN100496605C Vaccine for treatment of tubercolosis and other intracellular infections diseases and preparing process thereof |
| 06/10/2009 | CN100496505C Nano emulsion containing ginsenoside, preparation method and usage |
| 06/10/2009 | CN100496503C Nano emulsion containing ginsenoside, preparation method and usage |
| 06/10/2009 | CN100496501C Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist |